Ethicon, a medical device company of the Johnson & Johnson family of companies, announced a definitive agreement to acquire NeuWave Medical, Inc., a privately held medical device company that manufactures and markets minimally invasive soft tissue microwave ablation systems. Their products are currently used by physicians in over half of the top cancer centres in the United States.
This acquisition is consistent with the Johnson & Johnson Medical Devices’ strategy of advancing innovation and investing in areas of unmet medical needs such as surgical oncology. Financial terms of the transaction have not been disclosed.
NeuWave Medical’s ablation technology was originally developed by physicians and microwave scientists from the University of Wisconsin to maximize energy delivery to tissue, minimize invasiveness and provide physician-friendly workflow. NeuWave Medical’s Certus 140 ablation system’s high-powered computer and intuitive touchscreen interface enables activation of single or simultaneous multiple probe procedures for patients with soft tissue lesions. This allows physicians to effectively tailor ablations for lesions of varying shapes and sizes. NeuWave Medical’s probe family includes conventional probes and the only Precision PR probe to limit the ablation length, allowing precise and controlled ablations.